UNASSIGNED: The optimal sequence of @entity2600 and @entity901 -based regimens for metastatic @entity14 remains unclear. We conducted a population-based observational study by retrospectively reviewing records from Taiwan's National Health Insurance Research Database to explore this issue. @entity1 aged >= 20 years with metastatic @entity14 newly diagnosed between 2004 and 2008 (n = 9490) were enrolled in current study. Among these 9490 @entity1 , 3895 @entity1 (41.04%) did not receive any chemotherapy within the first three months after @entity16839 registration. @entity1 who received best supportive care were older and had higher Charlson comorbidity indexes and incidences of comorbidities than those who received @entity2600 -based regimens, @entity901 -based regimens, and @entity1487 / @entity416 alone. @entity1 who received @entity2600 followed by @entity901 -based regimens and those who received the reverse sequence were further stratified into arm A (n = 542) and arm B (n = 1156), respectively. The median first time to next treatment was not significantly different between arm A and arm B (210 days vs. 196 days; p = 0.17). However, the median second time to next treatment was longer in arm A than in arm B (155 days vs. 123 days; p = 0.006), which translated into a better overall survival (487 days vs. 454 days; p = 0.02). The crossover rate was higher in arm A than in arm B (47.84% vs. 41.61%; p<0.001). Multivariate Cox regression analyses showed that overall survival was comparable between the two chemotherapy sequences (p = 0.27). Our study suggested that @entity2600 followed by @entity901 -based regimens might be a better chemotherapy treatment option for metastatic @entity14 than the reverse sequence given the higher crossover rate and potential overall survival benefit.

Optimal Sequence of XXXX and @entity901 -Based Regimens in Metastatic @entity14 : A Population-Based Observational Study.

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity416 :: ('MESH:C110904', 'Chemical') :: ['capecitabine'] @entity16839 :: ('MESH:D002388', 'Disease') :: ['catastrophic illness'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-fluorouracil']
@entity2600 :: (MESH:C051890,Chemical) :: ['Irinotecan']
